Immunotherapy for Accessible Tumors Utilizing Delayed Hypersensitivity Reactions and Separated Components of the Immune System

Klein, Edmund; Holtermann, Ole A.; Milgrom, Halina; Case, Robert W.; Klein, David L.; Rosner, Dutzu; Djerassi, Isaac

doi:10.1016/s0025-7125(16)31888-0

Cited by 49 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings were supported by Mozzanica et al 18 who studied therapeutically induced regression of BCCs with an intralesional alpha interferon, and by Halliday et al 19 who reported spontaneous regression of primary melanoma and non‐melanoma skin cancers in association with infiltrating CD4+ T cells . Induction of contact dermatitis with topical sensitizing agents has also been postulated to lead to tumor eradication 20,21 …”

Section: Discussionmentioning

confidence: 99%

Effects of biopsy‐induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens

et al. 2003

View full text Add to dashboard Cite

Background: Wound healing following a partial biopsy of basal cell (BCC) and squamous cell carcinomas (SCC) may induce tumor regression. Methods: Nonmelanoma skin cancer (NMSC) biopsy and re-excision specimens from 1994 to 2001were reviewed for histologic evidence of scar vs. presence of residual tumor in excision specimens. Regressed and non-regressed tumors were analyzed to assess the influence of anatomic location, biopsy technique (punch vs. shave), histologic subtype of BCC or SCC, time interval between biopsy and excision, and patient age. Results: Nine hundred and ten excisions were performed for transected BCC or SCC, 217 (24%) of which showed scar with no residual tumor. Logistic regression analysis revealed significant differences in the regressed vs. non-regressed subsets. SCCs were more likely to regress than BCCs (40% vs. 20%, respectively, p < 0.00001). Independent of the NMSC type, tumors regressed more often following shave rather than punch biopsy (34% vs.15%, respectively, p < 0.00001), as did tumors on the trunk and extremities compared with head and neck cases (31% vs. 21%, respectively, p < 0.01). Conclusions: In our series, 24% of NMSCs transected on the initial biopsy showed no residual tumor in the excision specimens, implying that some event in the interval between biopsy and excision may lead to the eradication of residual tumor.The exact mechanism is unclear, but wound healing likely plays an important role.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of biopsy‐induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Topical 5% 5-FU [9,10] and topical DNCB [11] have been used for typical inva sive lesions of basal cell epithelioma, al though relapse rates of 50-70% have been reported [12]. Fluorouracil is thought to work by inhibiting DNA synthesis in the more undifferentiated, more rapid-growing malignant cells.…”

Section: Discussionmentioning

confidence: 99%

Basal Cell Nevus Syndrome

Hazen¹,

Taub²

1984

Dermatology

View full text Add to dashboard Cite

show abstract

“…Il conviendrait donc d'examiner, dans des essais thérapeutiques, si l'envahisse ment des ganglions par des cellules de mycosis, voire même les modifications histologiques non spécifiques qualifiées de dermatopathiques, ne seraient pas des indications d'une irradiation de tous les territoires ganglionnaires, comme on la réalise dans la maladie de Hodgkin. Il faudrait enfin évaluer l'action de l'immunothérapie dont l'efficacité semble suggérée par la rapidité et l'impor tance des réponses obtenues chez les malades qui se sensibilisent à l'ypérite azotée adminstrée en badigeonnages [9,19,27], La sensibilisation a été délibérément recherchée comme moyen thérapeutique, en utilisant, par exemple, le dinitrochlorobenzène [12], Le facteur de transfert a également été utilisée dans le traitement du mycosis fongoïde, avec quelques succès [28], En conclusion, presque tout reste à faire dans l'étude de la stratégie thérapeutique du mycosis fongoïde. Le polymorphisme de cette affection et sa rareté rendent nécessaire la création de groupes coopérateurs de dimen sion internationale pour réaliser des essais thérapeutiques capables d'apporter des réponses non équivoques dans un délai raisonnable.…”

Section: Discussion Et Conclusionunclassified

La chimiothérapie par voie generate dans le traitement du mycosis fongoïde

Kenis¹

1978

Dermatology

View full text Add to dashboard Cite

The clinical experience with chemotherapy in mycosis fungoides is practically limited to the action of different types of chemotherapeutic agents on the lesions in far-advanced cases. A large number of agents from almost all classes – alkylating agents, antimetabolites, antibiotics, alkaloids, hormones – have some efficacy in clearing skin lesions. Despite this fact, combination chemotherapy has been the subject of a very small number of publications with conflicting results. The influence on survival, the comparative effects of combination versus single-agent chemotherapy, the value of chemotherapy combined to other treatment modalities have not been submitted to scientific evaluation. Considering the low frequency of the disease and the great variability of the clinical picture, it seems mandatory to implement large cooperative trials, possibly on an international scale.

show abstract

Immunotherapy for Accessible Tumors Utilizing Delayed Hypersensitivity Reactions and Separated Components of the Immune System

Cited by 49 publications

References 18 publications

Effects of biopsy‐induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens

Effects of biopsy‐induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens

Basal Cell Nevus Syndrome

La chimiothérapie par voie generate dans le traitement du mycosis fongoïde

Contact Info

Product

Resources

About